Novo Nordisk AS filed a lawsuit against Hims & Hers Health, claiming patent infringement

Novo Nordisk announced on February 9th that it has filed a lawsuit against Hims & Hers for patent infringement regarding the compound semaglutide products sold in the U.S. market. Novo Nordisk claims that Hims misleads consumers and healthcare professionals into believing that these unapproved drugs have clinical benefits and safety through promotional activities highlighting their compound semaglutide products. Hims continues to illegally mass-produce injectable versions using non-standard raw materials, and these counterfeit products are endangering patient health and well-being. (Jiemian)